profit from every ₹100 of sales.
₹0₹100
Biocon
₹371.00+0.84% today
-5.0% in 1 year
1-year low ₹326.601-year high ₹440.70
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹157.57 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Biocon sold, what it kept, and what it did with the cash.
Sales went from ₹109 billion in 2023 to ₹168 billion in 2026, with ₹3.86 billion of profit last year.
SalesProfit
Biocon handed back more cash to shareholders than it generated last year.
₹908M
Free cash flow 2026₹823M
Bought back its own shares₹26M
Paid as dividends₹908M
Cash vs. debt₹24.2B vs. ₹154.3B
Biocon vs. similar companies
Biocon grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Biocon | 157.6× · Very expensive | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Biocon's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 109,341 | 141,958 | 150,522 | 167,799 | |
| 72,673 | 92,892 | 98,547 | 110,892 | |
| 16,271 | 14,345 | 14,793 | 14,986 | |
| 24,292 | 40,684 | 44,710 | 33,949 | |
| 4,627 | 10,225 | 10,133 | 3,856 | |
| 3.87 | 8.54 | 8.46 | 2.82 | |
| 66.5% | 65.4% | 65.5% | 66.1% | |
| 14.9% | 10.1% | 9.8% | 8.9% | |
| 4.2% | 7.2% | 6.7% | 2.3% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 520,428 | 560,707 | 587,973 | 636,506 |
| Cash | 13,232 | 12,334 | 32,267 | 24,165 |
| Total debt | 180,188 | 162,767 | 183,620 | 154,341 |
| Total liabilities | 295,540 | 307,959 | 310,848 | 270,291 |
| 178,669 | 197,837 | 216,440 | 340,318 | |
| 1,196 | 1,197 | 1,198 | 1,367 | |
| 2.9% | 5.5% | 5.5% | 2.3% | |
| 2.6% | 5.2% | 4.7% | 1.1% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 18,525 | 29,539 | 40,612 | 19,940 | |
| 17,263 | 19,316 | 23,433 | 19,117 | |
| 1,262 | 10,223 | 17,179 | 823 | |
| Dividends paid | 718 | 2,030 | 829 | 908 |
| 647 | 0 | 0 | 26 | |
| 1,376 | 1,006 | 1,370 | 1,639 |
Valuation
- 157.6×
- –
- –
- 2.0×
- 3.6×
- 738.3×
- 21.7×
- 0.1%
- 0.6%
- 0.1%
Profitability
- 66.1%
- 8.9%
- 2.3%
- –
- 2.2%
- 3.8%
- –
- –
- –
- –
Growth
- +15.3%
- −10.0%
- –
- –
- +4.6%
Financial health
- 3.8×
- 0.45
- –
- 1.5×
- 1.22
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 40%of 952
Top 50%of 883
Bottom 3%of 576
Top 37%of 870
Bottom 41%of 985
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
23.5% of its profit
Room to growStretchedMore than it earns: 110.3%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
42No pass
Philip Fisher
22No pass
Peter Lynch
32No pass
Joel Greenblatt
1No pass
Charlie Munger
14No pass
Terry Smith
13No pass
Questions about Biocon
Is Biocon a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Biocon AI analysis
What does Biocon do?
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. It is in Biotechnology, based in Bengaluru, India.
Does Biocon pay a dividend?
Yes. At today's price the dividend is 0.1% a year, about 24% of its yearly profit. In 2026 it paid out ₹908 million in dividends.
Is Biocon stock halal?
Yes. Biocon passes our halal screen: its business is permitted and its debt is 25% of its market value, under the 30% limit. How we check
How has Biocon stock done over the past year?
Down 5.0% over the past twelve months, to ₹371.00. It traded between ₹326.60 and ₹440.70 and is 15.8% below its high.
Who are Biocon's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Biocon's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.